Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
| 29.75 | |
| 29.5613 | |
| - | |
| 29.75 | |
| 29.5613 | |
| 26.91-58.6941 | |
| 29 365 M | |
| 982 M | |
| 47 013 M | |
| 2.2095 | |
| 0.004 | |
| 0.919 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SEATTLE (AP) — Ending an eight-year legal battle, chemical giant Monsanto has agreed to a $160-million settlement with Seattle for its part in polluting a river that runs through the heart of the ci...
By Jonathan Stempel (Reuters) - Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the loca...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
